Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud’s Phenomena.
Condition(s):Raynaud Phenomenon; Primary Raynaud Phenomenon; Raynaud Disease; Raynaud SyndromeLast Updated:November 5, 2020Terminated
Hide Studies Not Open or Pending
Condition(s):Raynaud Phenomenon; Primary Raynaud Phenomenon; Raynaud Disease; Raynaud SyndromeLast Updated:November 5, 2020Terminated
Condition(s):MigraineLast Updated:August 2, 2019Completed
Condition(s):Dyspepsia; Irritable Bowel SyndromeLast Updated:March 7, 2018Completed
Condition(s):Cluster HeadacheLast Updated:December 17, 2019Completed
Condition(s):Post-Traumatic HeadacheLast Updated:March 10, 2020Withdrawn
Condition(s):Chronic MigraineLast Updated:June 20, 2018Completed
Condition(s):MigraineLast Updated:August 19, 2019Completed
Condition(s):MigraineLast Updated:July 26, 2018Terminated
Condition(s):Migraine DisordersLast Updated:September 11, 2020Completed
Condition(s):Chronic Cluster HeadacheLast Updated:April 25, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.